KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Debt to Equity (2016 - 2023)

Historic Debt to Equity for Pacific Biosciences Of California (PACB) over the last 13 years, with Q3 2023 value amounting to $0.13.

  • Pacific Biosciences Of California's Debt to Equity changed N/A to $0.13 in Q3 2023 from the same period last year, while for Sep 2023 it was $0.13, marking a year-over-year change of. This contributed to the annual value of $0.31 for FY2022, which is 610591.97% up from last year.
  • As of Q3 2023, Pacific Biosciences Of California's Debt to Equity stood at $0.13.
  • In the past 5 years, Pacific Biosciences Of California's Debt to Equity ranged from a high of $0.31 in Q4 2022 and a low of $0.0 during Q4 2021
  • Over the past 4 years, Pacific Biosciences Of California's median Debt to Equity value was $0.28 (recorded in 2019), while the average stood at $0.21.
  • Per our database at Business Quant, Pacific Biosciences Of California's Debt to Equity surged by 12386.34% in 2019 and then skyrocketed by 610591.97% in 2022.
  • Pacific Biosciences Of California's Debt to Equity (Quarter) stood at $0.29 in 2019, then crashed by 98.28% to $0.0 in 2021, then surged by 6105.92% to $0.31 in 2022, then crashed by 58.92% to $0.13 in 2023.
  • Its last three reported values are $0.13 in Q3 2023, $0.29 for Q2 2023, and $0.27 during Q1 2023.